8 min listen
Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
ratings:
Length:
15 minutes
Released:
Jan 12, 2023
Format:
Podcast episode
Description
Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ. Related Content: Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
Released:
Jan 12, 2023
Format:
Podcast episode
Titles in the series (100)
Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial: Interview with David J. A. Jenkins, MD, author of Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial by JAMA Author Interviews